Having demonstrated the critical role of RORγ in reprogramming of TNBC de novo cholesterol biosynthesis in vitro, we sought to examine whether RORγ antagonists inhibit tumor growth through blocking aforementioned reprogramming. The gene discussed is RORC; the disease is neoplasm.